JUNIPER PUBLISHERS-CURRENT RESEARCH IN DIABETES & OBESITY JOURNAL

PHARMACOLOGICAL TREATMENT OF A PATIENT WITH LIFE-LONG OBESITY AND HETEROZYGOUS COMPLETE LOSS-OF-FUNCTION MELANOCORTIN 4 RECEPTOR MUTATION 



Authored by Emily Cooper


The heterozygous melanocortin 4 receptor (MC4R) mutation is considered a primary factor in 2% to 4% of patients with obesity. Pharmacological treatment, including long-term, is emerging as a new standard for obese patients; however, there are no published reports on treatment outcomes in obese patients with documented MC4R mutations. Weight loss occurs with diet restriction or bariatric surgery and is often followed by a weight regain phase in patients with or without the MC4R mutation, indicating the need for an alternative approach to weight loss such as pharmacological treatment.
This case study describes a 48-year-old woman who experienced lifelong obesity and a history of dieting that started in childhood with episodes of weight loss followed by weight gain. Her highest weight was 320 pounds in 2007. Her family’s medical history included diabetes, prediabetes, and obesity. She presented to the clinic in January 2013 weighing 286.2 pounds with at-risk cardiovascular and cardiometabolic profiles. Treatment was initiated to control insulin resistance and metabolic syndrome, lower cholesterol and triglycerides, and manage hypothyroidism. Weight-loss treatment also began with a combination of bupropion and naltrexone or carbonic anhydrase inhibitors and naltrexone. Her on-treatment nutrition included eating from all food groups without counting calories or excessive exercise. In late 2014, she tested positive for a heterozygous complete loss-of-function MC4R gene mutation and weighed 213 pounds. The patient’s lowest weight while on treatment was 166 pounds in August 2015. By November 2016, after experiencing partial weight regain, her weight had been stable for 6 months at approximately 198 pounds,a 30% reduction in weight from 2013.




For More articles in Diabetes & Obesity Please Click on: https://juniperpublishers.com/crdoj/index.php


For More Open Access Journals In Juniper Publishers Please Click on: https://juniperpublishers.com/index.php
 

 
 

Comments

Post a Comment

Popular posts from this blog

Psychological Predictors of Weight Loss Success Following Roux-en-Y Gastric Bypass _Juniper Publishers

Image
  CURRENT RESEARCH IN DIABETES & OBESITY JOURNAL JUNIPER PUBLISHERS   Authored by Hazem N Shamseddeen   Abstract Background: Weight loss is a primary outcome measure for the success of Roux-En-Y gastric bypass (RYGB). Much attention has been paid to the negative effects of psychology on postoperative weight loss. We sought to identify personality traits and eating habits that predict weight loss success following RYGB. Methods: A single psychologist prospectively evaluated 346 patients, who subsequently underwent laparoscopic RYGB. Psychological evaluation included Minnesota Multiphasic Personality Inventory Short Form (MMPI-2 SF) and long form subscales (MMPI-2 RC) as well as Overeating Questionnaire (OQ). Demographic, anthropomorphic, and clinical data were collected before and after surgery. Results: The overall mean percent excess weight loss (%EWL) was 71.34+/-24.35%. Of the ten MMPI-2 SF scales, Masculine-Feminine (MF), Hypochondriasis (HS)...
Read more

Studies on Glucagon Receptor and Antagonists of Glucagon Receptor for the Management of Diabetes Mellitus

Image
  CURRENT RESEARCH IN DIABETES & OBESITY JOURNAL   JUNIPER PUBLISHERS Authored by Ghulam Abbas Abstract Glucagon receptor plays an important role in the glucose homeostasis and thus is drug target for the management of hyperglycemia in type-2 diabetes mellitus. The suppression of glucagon secretion from the alpha-cells is the key to control hyperglycemic condition. The identification of non-peptide antagonists of glucagon receptor is an effective therapeutic approach to inhibit the glucagon secretion to achieve normal glucose index. Keywords:  Glucagon receptor; Hyperglycemia; Diabetes mellitus; Antagonists Go to Introduction Background Diabetes mellitus is a chronic metabolic disorder which is spreading at an alarming rate all over the world. Glucagon receptor belongs to the G protein-coupled receptors (GPCRs) superfamily and an important drug target for type-2 diabetes [1]. G-Proteins (guanine nucleotide binding proteins) actually act as molecular switches to turn o...
Read more

How Juniper Publishers Promotes Open Science

Juniper Publishers plays a pivotal role in advancing open science by fostering accessibility, transparency, and collaboration within the global research community. Their commitment to open science is reflected through various initiatives that remove barriers to knowledge and promote the dissemination of research findings.   1. Open Access Journals One of the primary ways Juniper Publishers promotes open science is through its open-access publishing model. By offering free and unrestricted access to scientific research articles, they ensure that anyone, regardless of their location or financial resources, can access valuable scientific knowledge. This open-access approach dismantles the paywall barriers typically associated with traditional publishing, thus making research accessible to a wider audience, including researchers, students, policymakers, and the general public. 2. Encouraging Collaboration and Networking Juniper Publishers fosters an environment that encourages coll...
Read more